Association Between Osteoprotegerin G1181C and T245G Polymorphisms and Diabetic Charcot Neuroarthropathy
Open Access
- 5 June 2009
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 32 (9), 1694-1697
- https://doi.org/10.2337/dc09-0243
Abstract
OBJECTIVE: Charcot neuroarthropathy is a disabling complication of diabetes. Although its pathogenesis remains unknown, we suppose that genetics may play a relevant role. RESEARCH DESIGN AND METHODS: We performed a case-control study with 59 subjects with diabetic Charcot neuroarthropathy (Ch group), 41 with diabetic neuropathy without Charcot neuroarthropathy (ND group), and 103 healthy control subjects (H group) to evaluate the impact of two single nucleotide polymorphisms (SNPs) of the osteoprotegerin gene (G1181C and T245G) on the risk of Charcot neuroarthropathy. RESULTS: Regarding the SNPs of G1181C, we found a significant linkage between the G allele and Charcot neuroarthropathy (Ch vs. ND, odds ratio [OR] 2.32 [95% CI 1.3–4.1], P = 0.006; Ch vs. H, 2.10 [1.3–3.3], P = 0.002; and ND vs. H, 0.90 [0.7–1.9], P = 0.452); similarly, we found a linkage with the G allele of T245G (Ch vs. ND, 6.25 [2.2–19.7], P < 0.001; Ch vs. H, 3.56 [1.9–6.7], P = 0.001; and ND vs. H, 0.54 [0.6–5.7], P = 0.304), supporting a protective role for the allele C and T, respectively. For this reason we investigated the frequency of the protective double homozygosis CC + TT (7% in Ch) that was significantly lower in Ch compared with H (0.18 [0.06–0.5], P = 0.002) and with ND (0.17 [0.05–0.58], P = 0.006), whereas there was no difference between H and ND (1.05 [0.43–2.0], P = 0.468). In a multivariate logistic backward regression model, only weight and the lack of CC and TT genotypes were independently associated with the presence of Charcot neuroarthropathy. CONCLUSIONS: This is the first study that shows an association between genetic regulation of bone remodeling and Charcot neuroarthropathy.Keywords
This publication has 23 references indexed in Scilit:
- Osteoporosis among patients with type 1 and type 2 diabetesDiabetes & Metabolism, 2008
- Multiple Genetic Loci for Bone Mineral Density and FracturesNew England Journal of Medicine, 2008
- Increased osteoclastic activity in acute Charcot’s osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligandDiabetologia, 2008
- Association between osteoprotegerin (OPG), receptor activator of nuclear factor-κB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal womenMenopause, 2007
- Regulation of Vascular Calcification by Osteoclast Regulatory Factors RANKL and OsteoprotegerinCirculation Research, 2004
- Sequence Variations in the Osteoprotegerin Gene Promoter in Patients with Postmenopausal OsteoporosisJournal of Clinical Endocrinology & Metabolism, 2002
- Minireview: The OPG/RANKL/RANK SystemEndocrinology, 2001
- The Prediction of Diabetic Neuropathic Foot Ulceration Using Vibration Perception Thresholds: A prospective studyDiabetes Care, 1994
- Radiographic Abnormalities in the Feet of Patients With Diabetic NeuropathyDiabetes Care, 1994
- NEURO-ARTHROPATHY (CHARCOT JOINTS) IN DIABETES MELLITUSMedicine, 1972